Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand

Abstract

AimsTo analyze the efficacy and safety of sofosbuvir (SOF)-based regimens in Thai patients with chronic hepatitis C virus infection who had pre-existing significant liver fibrosis. Patients and methodsThis was a retrospective cohort study, conducted between 1 June 2018 and 31 May 2019 at Rajavithi Hospital, Bangkok, Thailand. All patients completed 12 weeks of SOF-based regimens and had follow-up for at least 12 weeks after therapy discontinuation. The primary outcome was sustained virological response (SVR) 12 weeks after the end of therapy. ResultA total of 185 patients were included, with 52, 63 and 70 taking SOF+Ledipasvir (SOF +LDV), SOF+LDV+ribavirin (RBV) and SOF+Pegylated interferon (Peg-IFN)+RBV (SOF +Peg-IFN+RBV) respectively. Genotype (GT) 1 was predominant at 40.0%, followed by GT3 at 37.8%, and GT6 at 22.2%. Overall 95.1% of patients in this study achieved SVR (n = 176/185), and the only factor associated with SVR was HCV genotype (p = 0.001). GT6 patients had lower SVR rates compared to GT1 and GT3 patients (82.9%, 98.6%, and 98.6% respectively) while there was no association between SVR and other factors (p >0.05) such as gender, age, BMI, underlying cirrhosis, baseline HCV viral load, or prior treatment history. No serious adverse events were reported in the present study.

Real‐world effectiveness and safety of direct‐acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi‐Ter2 Study

“…Tran et al suggested that obesity, defined as BMI ≥ 30 kg/m2, did not have negative impact on virological response of CHC patients treated with DAA agents 29 . This observation was further confirmed by several other authors 30,31 . However, in a large study of 6961 patients treated with 8 or 12 weeks of LDV/SOF ± RBV or 12 weeks of OPrD ± RBV, high BMI was found to be a significant negative predictor of SVR 32 .…”

“…29 This observation was further confirmed by several other authors. 30,31 However, in a large study of 6961 patients treated with 8 or 12 weeks of LDV/ SOF ± RBV or 12 weeks of OPrD ± RBV, high BMI was found to be a significant negative predictor of SVR. 32 Considerably lower SVR rates for patients with significant steatosis based on biopsy samples compared to controls have also been reported after interferon (IFN)/ ribavirin or pegylated IFN/ribavirin therapies.…”

Real‐world treatment outcomes of sofosbuvir‐based regimens for treatment of chronic hepatitis C with and without human immunodeficiency virus co‐infection

“…The overall SVR rate (96.9%) was comparable to previously reported findings. 15 , 16 , 17 , 18 The rate of SVR in real‐world setting was not different between the HCV mono‐infection group and the HIV/HCV co‐infection group (96.9% vs 96.9%, respectively). Several previously reported studies have shown the same response.…”

“…Our finding was the same as previously reported real‐word setting outcomes in Thailand. 16 This could potentially be explained by limited efficacy of SOF‐based regimens for GT6 infection and the small sample size. In contrast, Two studies from New Zealand ( n = 25) and United States ( n = 64) reported overall SVR rate was 96% and 95% respectively with 12 weeks of SOF/LDV.…”

pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma

“…The pathogenesis of HCC is strongly correlated with chronic infection of hepatitis B virus, hepatitis C virus, alcoholic liver cirrhosis, etc. [ 2 , 3 ]. Conventional treatments, for patients at early stages of HCC, include surgery, radiotherapy, interventional therapy and radiofrequency ablation [ 4 ].…”